Shopping Cart 0
Cart Subtotal
USD 0

Bio-Path Holdings Inc (BPTH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Bio-Path Holdings Inc (Bio-Path) is a clinical stage biotechnology company that develops targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company provides products pipeline such as prexigebersen (Liposomal Grb2 Antisense) and BP1002 (Liposomal Bcl2). Its prexigebersen (Liposomal Grb2 Antisense), is developed for the treatment of Acute Myeloid Leukemia (AML) and solid tumors. Bio-Path's BP1002 (Liposomal Bcl2) is used for the treatment of lymphoma, leukemia, colon, prostate and breast cancers. The company's proprietary liposomal delivery and antisense technology platform DNAbilize, is used to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path is headquartered in Bellaire, Texas, the US.

Bio-Path Holdings Inc (BPTH)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Bio-Path Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Bio-Path Enters into Research Agreement with Thomas Jefferson University 12

Bio-Path Enters into Research Agreement with University of Texas MD Anderson Cancer Center 13

Equity Offering 14

Bio-Path Holdings Raises USD1.5 Million in Private Placement of Shares 14

Bio-Path Holdings Raises USD4 Million in Private Placement of Shares 15

Bio-Path Raises USD10 Million in Private Placement of Units 16

Bio-Path Raises USD15 Million in Private Placement of Shares and Warrants 17

Bio-Path Holdings Completes Private Placement Of Shares For USD 0.01 Million 19

Bio-Path Holdings Completes Private Placement Of Shares For USD 0.45 Million 20

Bio-Path Holdings Completes Private Placement Of USD 0.08 Million 21

Bio-Path Holdings Inc-Key Competitors 22

Bio-Path Holdings Inc-Key Employees 23

Bio-Path Holdings Inc-Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Recent Developments 25

Financial Announcements 25

Aug 15, 2018: Bio-Path Holdings announces second quarter 2018 financial results 25

May 16, 2018: Bio-Path Holdings Reports First Quarter 2018 Financial Results 27

Apr 03, 2018: Bio-Path Holdings Reports Full Year 2017 Financial Results 28

Nov 09, 2017: Bio-Path Holdings Reports Third Quarter 2017 Financial Results 29

Aug 10, 2017: Bio-Path Holdings Reports Second Quarter 2017 Financial Results 30

May 11, 2017: Bio-Path Reports First Quarter 2017 Financial Results 31

Mar 15, 2017: Bio-Path Holdings Reports Full Year 2016 Financial Results 32

Corporate Communications 33

Aug 16, 2018: Bio-Path Holdings Appoints Dr. Jason B. Fleming to Scientific Advisory Board 33

May 10, 2018: Bio-Path Holdings Appoints Dr. Anas Younes to Scientific Advisory Board 34

Feb 05, 2018: Bio-Path Holdings names Paul Aubert as Board Director 35

Jul 17, 2017: Bio-Path Holdings Appoints Mark Colonnese to its Board of Directors 36

Product News 37

11/06/2017: Bio-Path Holdings Highlights Advancements in Preclinical Discovery Efforts 37

03/15/2018: Bio-Path Holdings to Present Data at the 2018 AACR Annual Meeting 38

Clinical Trials 39

Apr 03, 2018: Bio-Path Holdings Announces Interim Data from Phase 2 Clinical Trial of Prexigebersen in Combination with Low Dose Cytarabine (LDAC) for the Treatment of Acute Myeloid Leukemia (AML) 39

Mar 29, 2018: Bio-Path Holdings Announces Publication in The Lancet Haematology 40

Dec 29, 2017: Bio-Path Holdings Provides Clinical Update on Lymphoma Drug BP-1002 41

Dec 29, 2017: Bio-Path Holdings Provides Clinical Update on Prexigebersen 42

Apr 05, 2017: Bio-Path Holdings Presents Results Showing Potential of BP1002 as Treatment for Aggressive Non-Hodgkins Lymphoma 43

Mar 10, 2017: Bio-Path Holdings to Present Data at the 2017 AACR Annual Meeting 44

Other Significant Developments 45

Jun 20, 2017: Bio-Path Holdings: Update to Shareholders 45

Appendix 46

Methodology 46

About GlobalData 46

Contact Us 46

Disclaimer 46


List Of Figure

List of Figures

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Bio-Path Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Bio-Path Holdings Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Bio-Path Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Bio-Path Enters into Research Agreement with Thomas Jefferson University 12

Bio-Path Enters into Research Agreement with University of Texas MD Anderson Cancer Center 13

Bio-Path Holdings Raises USD1.5 Million in Private Placement of Shares 14

Bio-Path Holdings Raises USD4 Million in Private Placement of Shares 15

Bio-Path Raises USD10 Million in Private Placement of Units 16

Bio-Path Raises USD15 Million in Private Placement of Shares and Warrants 17

Bio-Path Holdings Completes Private Placement Of Shares For USD 0.01 Million 19

Bio-Path Holdings Completes Private Placement Of Shares For USD 0.45 Million 20

Bio-Path Holdings Completes Private Placement Of USD 0.08 Million 21

Bio-Path Holdings Inc, Key Competitors 22

Bio-Path Holdings Inc, Key Employees 23

Bio-Path Holdings Inc, Subsidiaries 24

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Bio-Path Holdings Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Bio-Path Holdings Inc (Bio-Path) is a clinical stage biotechnology company that develops targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company provides products pipeline such as prexigebersen (Liposomal Grb2 Antisense) and BP1002 (Liposomal Bcl2). Its prexigebersen (Liposomal Grb2 Antisense), is developed for the treatment of Acute Myeloid Leukemia (AML) and solid tumors. Bio-Path's BP1002 (Liposomal Bcl2) is used for the treatment of lymphoma, leukemia, colon, prostate and breast cancers. The company's proprietary liposomal delivery and antisense technology platform DNAbilize, is used to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path is headquartered in Bellaire, Texas, the US.

Bio-Path Holdings Inc (BPTH)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Bio-Path Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Bio-Path Enters into Research Agreement with Thomas Jefferson University 12

Bio-Path Enters into Research Agreement with University of Texas MD Anderson Cancer Center 13

Equity Offering 14

Bio-Path Holdings Raises USD1.5 Million in Private Placement of Shares 14

Bio-Path Holdings Raises USD4 Million in Private Placement of Shares 15

Bio-Path Raises USD10 Million in Private Placement of Units 16

Bio-Path Raises USD15 Million in Private Placement of Shares and Warrants 17

Bio-Path Holdings Completes Private Placement Of Shares For USD 0.01 Million 19

Bio-Path Holdings Completes Private Placement Of Shares For USD 0.45 Million 20

Bio-Path Holdings Completes Private Placement Of USD 0.08 Million 21

Bio-Path Holdings Inc-Key Competitors 22

Bio-Path Holdings Inc-Key Employees 23

Bio-Path Holdings Inc-Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Recent Developments 25

Financial Announcements 25

Aug 15, 2018: Bio-Path Holdings announces second quarter 2018 financial results 25

May 16, 2018: Bio-Path Holdings Reports First Quarter 2018 Financial Results 27

Apr 03, 2018: Bio-Path Holdings Reports Full Year 2017 Financial Results 28

Nov 09, 2017: Bio-Path Holdings Reports Third Quarter 2017 Financial Results 29

Aug 10, 2017: Bio-Path Holdings Reports Second Quarter 2017 Financial Results 30

May 11, 2017: Bio-Path Reports First Quarter 2017 Financial Results 31

Mar 15, 2017: Bio-Path Holdings Reports Full Year 2016 Financial Results 32

Corporate Communications 33

Aug 16, 2018: Bio-Path Holdings Appoints Dr. Jason B. Fleming to Scientific Advisory Board 33

May 10, 2018: Bio-Path Holdings Appoints Dr. Anas Younes to Scientific Advisory Board 34

Feb 05, 2018: Bio-Path Holdings names Paul Aubert as Board Director 35

Jul 17, 2017: Bio-Path Holdings Appoints Mark Colonnese to its Board of Directors 36

Product News 37

11/06/2017: Bio-Path Holdings Highlights Advancements in Preclinical Discovery Efforts 37

03/15/2018: Bio-Path Holdings to Present Data at the 2018 AACR Annual Meeting 38

Clinical Trials 39

Apr 03, 2018: Bio-Path Holdings Announces Interim Data from Phase 2 Clinical Trial of Prexigebersen in Combination with Low Dose Cytarabine (LDAC) for the Treatment of Acute Myeloid Leukemia (AML) 39

Mar 29, 2018: Bio-Path Holdings Announces Publication in The Lancet Haematology 40

Dec 29, 2017: Bio-Path Holdings Provides Clinical Update on Lymphoma Drug BP-1002 41

Dec 29, 2017: Bio-Path Holdings Provides Clinical Update on Prexigebersen 42

Apr 05, 2017: Bio-Path Holdings Presents Results Showing Potential of BP1002 as Treatment for Aggressive Non-Hodgkins Lymphoma 43

Mar 10, 2017: Bio-Path Holdings to Present Data at the 2017 AACR Annual Meeting 44

Other Significant Developments 45

Jun 20, 2017: Bio-Path Holdings: Update to Shareholders 45

Appendix 46

Methodology 46

About GlobalData 46

Contact Us 46

Disclaimer 46


List Of Figure

List of Figures

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Bio-Path Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Bio-Path Holdings Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Bio-Path Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10

Bio-Path Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Bio-Path Enters into Research Agreement with Thomas Jefferson University 12

Bio-Path Enters into Research Agreement with University of Texas MD Anderson Cancer Center 13

Bio-Path Holdings Raises USD1.5 Million in Private Placement of Shares 14

Bio-Path Holdings Raises USD4 Million in Private Placement of Shares 15

Bio-Path Raises USD10 Million in Private Placement of Units 16

Bio-Path Raises USD15 Million in Private Placement of Shares and Warrants 17

Bio-Path Holdings Completes Private Placement Of Shares For USD 0.01 Million 19

Bio-Path Holdings Completes Private Placement Of Shares For USD 0.45 Million 20

Bio-Path Holdings Completes Private Placement Of USD 0.08 Million 21

Bio-Path Holdings Inc, Key Competitors 22

Bio-Path Holdings Inc, Key Employees 23

Bio-Path Holdings Inc, Subsidiaries 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Bio-Path Holdings Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.